China Pharma Holdings, Inc. - CPHI Business Value to Revenue

Public company logo of China Pharma Holdings (CPHI)

China Pharma Holdings (CPHI) maintains its margins through regional sales while resisting regulatory pricing pressure. The company's price-to-sales trend confirms this stability, where 4433.87 shows the value of this parameter. The business relies on its status as a key supplier to state hospitals, integrating manufacturing with distribution. Meanwhile, technological progress has stalled, limited only to line updates and compliance.

CPHI China Pharma Holdings Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/21/2026

Financial and market metric breakdowns for China Pharma Holdings, Inc. (CPHI)

Initial company analysis:China Pharma Holdings Inc.
Mass-produced product of chinapharmaholdings.com

This metric compares the total enterprise value, including debt and subtracting cash, against generated revenue to determine the actual market premium paid per unit of sales. By analyzing the enterprise value-to-revenue ratio, an investor assesses the capitalization efficiency of China Pharma Holdings (CPHI), whose stable revenue streams from generic drug sales make this indicator a reliable valuation tool within the defensive sector.